ライフサイエンスコーパス: ATV

1 ATV alone or in combination with PIO markedly augmented

2 ATV and PIO at 5 and 10 mg x kg(-1) . d(-1) significantl

3 ATV as an adjunct to SRP can provide a new direction in

4 ATV decreased bone loss, reduced MPO, TNF-alpha, IL-1bet

5 ATV has a distinct resistance profile relative to other

6 ATV particles in late and recycling endosome compartment

7 ATV reduced inflammation, oxidative stress, and bone los

8 ATV reduced RANKL and DKK-1 and increased OPG, WNT10b, a

9 ATV was found in biliary calculi in 8 of 11 cases: infra

10 ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-

11 ATV+DDI+FTC had inferior efficacy and is not recommended

12 ATV, however, retained sensitivity to perforin-mediated

13 ATV/r did not significantly affect boceprevir exposure,

14 g(-1) x d(-1); or PIO 10 mg x kg(-1) x d(-1)+ATV 10 mg x kg(-1) x d(-1).

15 s received water; PIO 10 mg x kg(-1) x d(-1)+ATV 10 mg x kg(-1) x d(-1); PIO+ATV and valdecoxib, a se

16 water; PIO 2, 5, or 10 mg x kg(-1) x d(-1); ATV 2, 5, or 10 mg x kg(-1) x d(-1); or PIO 10 mg x kg(-

17 into two treatment groups: 1) SRP plus 1.2% ATV and 2) SRP plus placebo.

18 PRF + 1.2% ATV and PRF alone showed significantly greater PD reduct

19 zed into two treatment groups: SRP plus 1.2% ATV and SRP plus placebo gel.

20 is to investigate the effectiveness of 1.2% ATV as an adjunct to scaling and root planing (SRP) in t

21 Thus, 1.2% ATV failed to augment the regenerative potential of PRF

22 1.2% RSV gel (group 2); and 3) SRP with 1.2% ATV gel (group 3).

23 nd compare the efficacy of 1.2% RSV and 1.2% ATV gel local drug delivery (LDD) and redelivery systems

24 o evaluate combined efficacy of PRF and 1.2% ATV gel with open flap debridement (OFD) in treatment of

25 ims to explore efficacy of 1.2% RSV and 1.2% ATV gels as a local drug delivery and redelivery system

26 r clinico-radiographic improvement than 1.2% ATV or placebo gels as adjunct to mechanical periodontal

27 Furthermore, PRF + 1.2% ATV showed a similar percentage radiographic defect dept

28 PRF + 1.2% ATV showed similar improvements in clinical parameters w

29 t with SRP followed by LDD of 1.2% RSV, 1.2% ATV, or placebo gel.

30 ups: 1) OFD with PRF; 2) OFD with PRF + 1.2% ATV; and 3) OFD alone.

31 roups: 1) naive; 2) EP; 3) GIOP + EP; and 4) ATV.

32 After ATV therapy, there was a significant decrease in LDL con

33 d by A. mexicanum as early as 24 hours after ATV infection.

34 .3), then TFV (3.52, 95% CI, 2.27-5.48), and ATV (2.39, 95% CI, 1.69-3.38).

35 tions at residue 50 affect how APV, DRV, and ATV bind the protease with altered van der Waals interac

36 To explain how APV, DRV, and ATV susceptibility are influenced by mutations at residu

37 BC/3TC and TDF/FTC groups (combining EFV and ATV/r arms; median change, -341 [interquartile range, -8

38 Groups GIOP + EP and ATV received 7 mg/kg dexamethasone intramuscularly once

39 Groups EP, GIOP + EP, and ATV were submitted to EP by ligature around the maxillar

40 mg; part B subjects receiving GSK3532795 and ATV +/- RTV achieved similar declines to those receiving

41 l fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28 days.

42 Both PIO and ATV increase myocardial levels of 15-epi-LXA4, a mediato

43 antiinflammatory properties of both PIO and ATV.

44 B-100 pool size (PS) in both the placebo and ATV groups.

45 tion containing a 1:1 molar ratio of RTV and ATV achieved only 50% of the supersaturation attained by

46 sing the Aptima Trichomonas vaginalis assay (ATV; Gen-Probe) and the prevalence of Chlamydia trachoma

47 GenProbe Aptima Trichomonas vaginalis assay; ATV) for T. vaginalis were compared with the Affirm VPII

48 Atazanavir (ATV) is a once-daily human immunodeficiency virus (HIV)

49 )-infected patients receiving an atazanavir (ATV)-based antiretroviral regimen developed complicated

50 RTV in the bidirectional TVR and atazanavir (ATV) interactions.

51 Ritonavir (RTV) and atazanavir (ATV) were co-formulated with polyvinylpyrrolidone to pro

52 ricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal and plasma s

53 e therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside rever

54 is observed in patients failing atazanavir (ATV) therapy.

55 d then received PI/r as follows: atazanavir (ATV) 300 mg once daily, lopinavir (LPV) 400 mg twice dai

56 ontaining the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogenization.

57 r (RTV) as a pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)/tenofovir d

58 V) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

59 80 mg GSK3532795 once daily with atazanavir (ATV) with or without (+/-) ritonavir (RTV) or standard o

60 ine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppressed plasma virus loads, blood and cerv

61 Atorvastatin (ATV) has shown pleiotropic effects on bone tissue, and o

62 Atorvastatin (ATV) is a specific competitive inhibitor of 3-hydroxy-2-

63 evaluate effectiveness of 1.2% atorvastatin (ATV) gel, as an adjunct to scaling and root planing (SRP

64 Rosuvastatin (RSV) and atorvastatin (ATV) are known to inhibit osteoclastic bone resorption a

65 Rosuvastatin (RSV) and atorvastatin (ATV) have shown bone stimulatory and anti-inflammatory e

66 tion platelet concentrate, and atorvastatin (ATV), a potent member of the statin group, are known to

67 ther placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks.

68 Patients received 80 mg atorvastatin (ATV) or matching placebo for a 12-week treatment period

69 We investigated whether atorvastatin (ATV) and pioglitazone (PIO) increase the myocardial cont

70 important role in the emergence of ATV, (b) ATV bearing a Fas-resistant phenotype was a chief conseq

71 There were no differences between ATV and placebo with regard to the surrogate markers mea

72 CV)/HIV-coinfected patients on a RTV-boosted ATV-based (ATVr) antiretroviral regimen (300/100 mg ever

73 For both ATV and TFV, FGT:plasma was significantly lower in parti

74 CONTEXT: Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor sy

75 Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a median follow-up of

76 did not significantly differ for concurrent ATV/r for 750 mg BID or 1500 mg BID when compared to the

77 were drawn from the injury survey; controls (ATV drivers who had not been injured) were drawn from th

78 Locally delivered ATV was found to be effective in treatment of intrabony

79 substitution were growth impaired, displayed ATV-specific resistance, and had increased susceptibilit

80 navir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-

81 ing a new nanovesicular system encapsulating ATV for its delivery via the transdermal route.

82 (90% confidence interval [CI], .55-.78) for ATV/r; 0.66 (90% CI, .60-.72) for LPV/r, and 0.56 (90% C

83 is compensated for by enhanced enthalpy for ATV binding to I50V variants and APV binding to I50L var

84 position for APV/DRV and the P2 position for ATV.

85 Furthermore, ATV group sites presented with a significantly greater p

86 Furthermore, ATV that survived CTL adoptive immunotherapy displayed a

87 Group ATV received 27 mg/kg ATV orally, and the others receive

88 The results revealed high ATV entrapment efficiency (EE%) ranging from 55.62 to 83

89 of the present investigation was to improve ATV bioavailability and overcome complications attendant

90 e pharmacoenhancer of the protease inhibitor ATV.

91 rveys conducted in 1997: a survey of injured ATV drivers treated in hospital emergency departments an

92 ovide important new resources to investigate ATV disease pathology and host-pathogen dynamics in natu

93 Group ATV received 27 mg/kg ATV orally, and the others received SAL 30 minutes befor

94 e performed a randomized trial of open-label ATV/r or EFV combined with abacavir/lamivudine (ABC/3TC)

95 nsdermal administration of nanotransfersomal ATV gel compared to oral ATV suspension.

96 ulated gene expression was characteristic of ATV.

97 The maximum achievable concentration of ATV decreased linearly as the mole fraction of ATV in th

98 promising alternative means for delivery of ATV.

99 Thus, the effects of ATV on experimental periodontitis (EP) in rats subjected

100 The effects of ATV/r and EFV upon safety and tolerability risk did not

101 played an important role in the emergence of ATV, (b) ATV bearing a Fas-resistant phenotype was a chi

102 -1 amino acid changes compared to failure of ATV/r-containing treatment.

103 V decreased linearly as the mole fraction of ATV in the formulation decreased and a similar trend was

104 r ATV clearance and higher predose levels of ATV compared to men.

105 Development and management of ATV-associated cholelithiasis are discussed.

106 ts and a survey of the general population of ATV users.

107 nificant determinants of immune selection of ATV in vivo.

108 e cohort of 388 patients, the sensitivity of ATV was 98.1% (53/54) versus 46.3% (25/54) for Affirm VP

109 The concept of ATVs has been in development for many years, and recentl

110 The boost effect of TVR on ATV exposure is higher than on RTV, despite its shorter

111 3TC with EFV (HR 2.46, 95% CI 1.20, 5.05) or ATV/r (HR 2.22, 95% CI 1.19, 4.14).

112 regimen modification for ABC/3TC with EFV or ATV/r and to safety events with EFV.

113 to 4 arms of ABC-3TC or TDF-FTC with EFV or ATV/r.

114 TC or TDF/FTC were not different with EFV or ATV/r.

115 an for TDF/FTC when given with either EFV or ATV/r.

116 ve ABC-3TC or TDF-FTC with open-label EFV or ATV/r.

117 and 10 each taking cART that included EFV or ATV/r.

118 ssigned (1:1) to receive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered onc

119 f nanotransfersomal ATV gel compared to oral ATV suspension.

120 rides and LDL cholesterol comparable to oral ATV.

121 (-1) x d(-1)+ATV 10 mg x kg(-1) x d(-1); PIO+ATV and valdecoxib, a selective cyclooxygenase-2 (COX-2)

122 tive cyclooxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor;

123 pi-LXA4 were significantly higher in the PIO+ATV group (1.29 +/- 0.02 ng/mg; P < 0.001 versus each ot

124 th valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had

125 PIO, ATV, and their combination resulted in a small increase

126 on of 5-lipoxygenase was not altered by PIO, ATV, or their combination.

127 r in magnitude among patients receiving PIs, ATV/r, or DRV/r but lowest among those receiving RAL.

128 t receiving cART, 8 of 10 subjects receiving ATV/r, and 2 of 10 subjects receiving EFV in combination

129 iver function tests than did those receiving ATV/RTV+FTC/TDF and had smaller median increases in fast

130 periencing virologic failure while receiving ATV-containing regimens contained a unique isoleucine-to

131 More recently, ATVs targeted to C-type lectin receptors have been explo

132 itabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL

133 ith efavirenz (EFV) or atazanavir-ritonavir (ATV/r).

134 ith efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected tr

135 itabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL.

136 itabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL

137 if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral therapy (cART) i

138 e, those assigned atazanavir plus ritonavir (ATV/r) did not have significantly more protease changes

139 ment responses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV) in initial antiretroviral regi

140 favirenz (EFV) or atazanavir plus ritonavir (ATV/r), on bone mineral density (BMD) have not been anal

141 Dissolution of an ASD containing RTV, ATV and lopinavir (LPV) was also investigated.

142 rsion containing a 1:1:1 molar ratio of RTV, ATV and LPV, the maximum concentration of each drug was

143 A second ATV TMA assay, utilizing an alternate T. vaginalis prime

144 Women had slower ATV clearance and higher predose levels of ATV compared

145 Lastly, such ATV displayed a diminished responsiveness in their expre

146 or mechanism in the immune selection of such ATV?

147 were significantly greater with RSV LDD than ATV or placebo gels at 6 and 9 months.

148 ectrometry analysis of calculi revealed that ATV made up a median of 89% (range, 10%-100%) of the tot

149 mouse lung metastasis model, we showed that ATV generated either naturally in vivo or in vitro by an

150 We speculate that ATV may be especially lethal to A. mexicanum and related

151 The ATV assay was performed on remnant Aptima Combo 2 specim

152 The ATV assay was statistically more sensitive than the Affi

153 The ATV AUC(0-12), C(max), and C(min) values were 39% (13%-6

154 To test this hypothesis directly, the ATV vIF2alphaH gene (ORF 57R) was deleted by homologous

155 80% +/- 8.35%, 41.86% +/- 6.76%) than in the ATV group (25.54% +/- 8.89%, 34.31% +/- 8.04%) at 6 and

156 e of radiographic bone fill was found in the ATV group (35.49% +/- 5.50%) compared to the placebo gro

157 l CAL were seen in the RSV group than in the ATV group at 6 and 9 months.

158 uction and mean CAL gain were greater in the ATV group than the placebo group at 3, 6, and 9 months.

159 duction and mean RAL gain was greater in the ATV group than the placebo group at 3, 6, and 9 months.

160 6% in the DRV/r [P = .42]; hip: -3.9% in the ATV/r group vs -3.4% in the DRV/r group [P = .36]) but w

161 ase inhibitor (PI) arms (spine: -4.0% in the ATV/r group vs -3.6% in the DRV/r [P = .42]; hip: -3.9%

162 fore, in a biologically relevant system, the ATV vIF2alphaH gene acts as an innate immune evasion fac

163 The TVQ assay was similar to the ATV assay (kappa=0.938) in direct analysis.

164 significantly greater DDR compared with the ATV group in treatment of mandibular Class II furcation

165 To maximize their stimulatory capacity, the ATVs are being evaluated with a variety of adjuvants or

166 res (21%) among 526 participants assigned to ATV+DDI+FTC and 76 (15%) among 519 participants assigned

167 Women assigned to ATV/r had a higher risk of virologic failure with either

168 an women assigned to EFV, or men assigned to ATV/r.

169 EVG/COBI/FTC/TDF was non-inferior to ATV/RTV+FTC/TDF for the primary outcome (316 patients [8

170 to virologic failure in women randomized to ATV/r compared to women randomized to EFV.

171 bearing I50V revealed specific resistance to ATV and amprenavir, respectively, with no evidence of cr

172 isolates exhibiting phenotypic resistance to ATV, emerged in a variety of different backgrounds and w

173 is the signature mutation for resistance to ATV.

174 Thirty-four subjects simplified to ATV/RTV alone, of whom 30 (88%) did not experience virol

175 Subjects switched to ATV/RTV at entry and discontinued NRTIs after 6 weeks.

176 Hologic Aptima Combo 2 (AC2) and Aptima TV (ATV), trichomonas microscopy, and culture.

177 more sensitive to interferon than wild-type ATV (wtATV).

178 The coadministration of TVR and unboosted ATV results in increased exposure of both drugs compared

179 e and after switching from ATVr to unboosted ATV (200 mg every 12 hours).

180 s of antibodies, antibody-targeted vaccines (ATV) are designed to deliver disease-specific antigens t

181 the TVQ assay, and the Aptima T. vaginalis (ATV) assay was performed using clinician-collected vagin

182 assay to the Gen-Probe Aptima T. vaginalis (ATV) transcription-mediated amplification (TMA) assay fo

183 e time select for aggressive tumor variants (ATV) in vivo?

184 determine and quantify all-terrain vehicle (ATV) risk factors.

185 (P = .024), respectively; and for EFV versus ATV/r were -1.7% and -3.1% (P = .035) and -3.1% and -3.4

186 A Tree Viewer (ATV) is a Java tool for the display and manipulation of

187 om the temperate Acidianus two-tailed virus (ATV) forms a high-affinity complex with RNAP by binding

188 m suggest that the Ambystoma tigrinum virus (ATV) eIF2alpha homologue (vIF2alphaH; open reading frame

189 ng viral pathogen, Ambystoma tigrinum virus (ATV).

190 ging consumers to dispose of the three-wheel ATVs still in use.

191 ater decreases in spine and hip BMD, whereas ATV/r led to more significant losses in spine, but not h

192 ated (353 with EVG/COBI/FTC/TDF and 355 with ATV/RTV+FTC/TDF).

193 I was noninferior to RTV in combination with ATV plus FTC/TDF at week 48.

194 l fat were found with RAL when compared with ATV/r or DRV/r over 96 weeks.

195 D-dimer declined with ATV/r and DRV/r and was unchanged with RAL.

196 of follow-up as follows: hsCRP declined with ATV/r and RAL, IL-6 declined only with RAL, and GLycA de

197 lure was similar for ABC/3TC vs TDF/FTC with ATV/r (hazard ratio [HR] 1.25, 95% confidence interval [

198 ivity against subtype B (monotherapy or with ATV +/- RTV) and subtype C, and was generally well toler

199 n various clinical settings were tested with ATV.

200 t study, simplified maintenance therapy with ATV/RTV alone maintained viral suppression in most subje

201 Early studies with ATVs focused on the ability to induce humoral immunity i